Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors

Experimental Oncology

Volumn 30, Issue 4, 2008, Pages 295-299

  Bereznaya, N M ^a   Kirnasovskaya, E A ^a   Vinnichuk, Yu D ^a   Belova, O B ^a   Lukyanova, N Yu ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Benign and malignant breast tumors; CD40; CD54; Cell proliferation; Drug resistance; LAK; p53

Indexed keywords

CD40 ANTIGEN; PARAFFIN; PROTEIN P53; INTERCELLULAR ADHESION MOLECULE 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGUS LYMPHOCYTE; BENIGN TUMOR; BREAST TUMOR; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CORRELATION ANALYSIS; DIFFUSION CHAMBER; DRUG RESISTANCE; EXPLANT; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; TUMOR CELL; BIOSYNTHESIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; METABOLISM;

ANTIGENS, CD40; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTES;

EID: 61449515239     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. D'Alimonte I, Flati V, D'Auro M, et al. Guanosine inhibits CD40 receptor expression and function induced by cytokines and beta amyloid in mouse microglia cells. J Immunol 2007; 178: 720-731 (Pubitemid 46095144)
2. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63: 4490-4496
3. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000; 50: 184-195
4. Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989; 8: 1403-1410
5. Bugajska U, Georgopoulos NT, Southgate J, et al. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst 2002; 94: 1381-1395
6. Sidorenko SP. Surface antigens of human cells systematized by international workshops on differentiation antigens of human leucocytes. Immunologiya Allergologiya 1998; 3: 16-38 (In Russian).
7. Bishop GA, Moore CR, Xie P, et al. TRAF proteins in CD40 signaling. Adv Exp Med Biol 2007; 597: 131-151
8. Ottaiano A, Pisano C, De Chiara A, et al. CD40 activation as potential tool in malignant neoplasms. Tumori 2002; 88: 361-366
9. Hock BD, McKenzie JL, Patton NW, et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 2006; 106: 2148-2157
10. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
11. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4: 360-367
12. Bereznaya NM, Chekhun VF. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp Oncol 2007; 29: 2-12.
13. Biancone L, Cantaluppi V, Boccellino M, et al. Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma. J Immunol 1999; 163: 6201-6208
14. Gu T, Zhu YB, Chen C, et al. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response. Cell Mol Immunol 2008; 5: 33-39
15. Shorts L, Weiss JM, Lee JK, et al. Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J Immunol 2006; 176: 6543-6552
16. Hill SC, Youde SJ, Man S, et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005; 174: 41-50.
17. Alexandroff AB, Jackson AM, Paterson T, et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000; 37: 515-526
18. Murugaiyan G, Martin S, Saha B. Levels of CD40 expression on dendritic cells dictate tumour growth or regression. Clin Exp Immunol 2007; 149: 194-202.
19. Voorzanger-Rousselot N, Alberti L, Blay JY. CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer 2006; 6: 75.
20. Berezhnaya NM, Vinnichuk UD, Konovalenko VF, et al. The sensitivity of chemioresistant human tumor explants to lysis by activated and nonactivated autological lymphocytes: a pilot study. Exp Oncol 2005; 27: 303-307
21. Samsonova EA, Maximova NA, Urmancheeva AF, et al. Expression of receptors of esrogens, progesterone and Heγ2 oncoprotein as an index of clinical course and outcome of endometryoid adenocarcinoma of corpus uteri (immunohistochemical study). Voprosi Oncologii 2004; 50: 196-201 (In Russain).
22. Berezhnaya NM, Kovalchuk EV. LAK-phenomenon (cell phenotype, mechanism of action and conditions for its realization). Immunologiya 1995; 2: 12-16 (In Russian).
23. Berezhnaya NM, Goretskiy BA. Interleukin-2 and malignant tumors. Kyiv: Naukova Dumka, 1992. 172 p (In Russian).
24. Rabinowich H, Herberman RB, Whiteside TL. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol 1993; 152: 481-498
25. De Paola F, Ridolfi R, Riccobon A, et al. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2. Br J Cancer 2003; 88: 320-326
26. Savas B, Kerr PE, Pross HF. Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma. Cancer Cell Int 2006; 3: 6-24.
27. Berezhnaya NM, Chekhun VF. System of interleukins and cancer. Kyiv: DIA, 2000. 224 p (In Russian).
28. Liebau C, Merk H, Schmidt S, et al. Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells. Cytokines Cell Mol Ther 2002; 7: 135-142
29. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13: 1083-1088
30. Lee JK, Seki N, Sayers TJ, et al. Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell Immunol 2005; 235: 145-152
31. Rowland SL, Tremblay MM, Ellison JM, et al. A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling. J Immunol 2007; 179: 4645-4653
32. Pinzon-Charry A, Schmidt CW, Lopez JA. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Res 2006; 8: 402.
33. von Bergwelt-Baildon M, Maecker B, Schultze J, et al. CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol 2004; 15: 853-857